Search the Marketing Knowledge Center

Reset Search

Narrow Your Search

Date Range

Topics

Industries

Regions

Products

Archived Content

Search terms:   
 All Words    Any Words    Exact Phrase   Sort by: 

Search returned: 14 document(s).

2013 Lessons Learned and 2014 Practical Tips

There were significant changes in almost every aspect of the law relating to advertising, marketing and promotions in 2013. Davis & Gilbert LLP explains what happened and offers suggestions for advertisers and agencies to think about and address in 2014.

FDA Proposes to Ease Rules for Pharmaceutical Ads on Social Media

Recently, the Food and Drug Administration issued a draft guidance that proposes to make advertising prescription products on social media less burdensome. Comments are due on the FDA’s draft guidance within ninety days.

Washington Update

Dan Jaffe, group EVP, government relations, ANA, discussed the latest issues in Washington regarding ad taxes, food advertising to children, ICANN’s proposed top-level domain (TLD) program, and online piracy best practices.

Pharmaceutical Marketing

This Kantar Media-sponsored article from Ad Age looks at the challenges and impending transitions facing the pharmaceutical industry.

2011 Compendium of Legislative, Regulatory, and Legal Issues

This document outlines the advocacy efforts of our Government Relations team in 2011.

Update on Legislative and Regulatory Issues

Dan Jaffe, EVP, government relations, ANA, provided updates on a number of issues including the national debt ceiling, tax reform, self-regulation, and ICANN.

Marketing Moratorium: The Pharmaceutical Industry and D.C.

Dan Jaffe, EVP, government relations, ANA, discussed legal and regulatory issues that may impact the pharmaceutical industry.

Making Mobile Happen in Pharmaceutical Marketing

Jose Cornejo, Mobile Health, Augme Tech, and Michelle Monte, account supervisor, Augme Mobile Health, Augme Tech, discussed how pharmaceutical companies can get involved in the mobile space.

Social Media: Opportunities and Challenges for the Pharmaceutical Industry

Keri S. Bruce, associate, ReedSmith, discussed the challenges facing pharmaceutical companies that are trying to enter the world of social media.

Washington and the Internet: Does Washington Want the Truth? (Welcome to the Bully Pulpit)

Douglas J. Wood, partner, Reed Smith, LLC, discussed the current hurdles, government regulations, risks, and best practices for marketers in relation to digital media and the internet.

Washington and the Internet: Does Washington Want the Truth? (Welcome to the Bully Pulpit)

Douglas J. Wood, partner, Reed Smith, LLC, discussed the current hurdles, government regulations, risks, and best practices for marketers in relation to digital media and the internet.

Pharmaceutical Marketing: Navigating the Complex Waters

Dan Jaffe, executive vice president, government relations at ANA, and Bruce Grant, senior vice president, business strategy at Digitas Health, discussed how federal legislation and social media are impacting pharmaceutical marketing.

Legislative and Regulatory Update

Dan Jaffe, EVP, government relations, ANA, provided a legislative and regulatory update, covering issues relating to financial reform legislation, privacy policies, the new Supreme Court vacancy, and the FTC's attempts to gain more rulemaking authority.

The FDA and Advertising

Joshua M. Sharfstein, principal deputy commissioner, Food and Drug Administration (FDA), shared his thoughts on how advertisers can work together with the FDA to improve public health.